ARTICLE | Emerging Company Profile
Hyku: tapping new targets by taking chemoproteomics beyond cysteine
In co-leading Hyku’s $56M seed round, RA Capital added to its portfolio of chemoproteomics companies
October 10, 2023 12:01 AM UTC
Chemoproteomics company Hyku is expanding the druggable proteome with a library of small molecules targeting histidine, tyrosine and lysine residues, and a cell-based screening method that enables the company to quickly determine to which proteins they bind.
Hyku Biosciences Inc. was incubated by RA Ventures, and announced a $56 million seed round last month co-led by RA Capital, Droia Ventures and Novartis Venture Fund...